Learn More
Podocytes participate in the formation and regulation of the glomerular filtration barrier. Loss of podocytes occurs during the early stages of diabetic nephropathy and impairs glomerular filtration. Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used as anti-diabetic agents in clinical practice. In this study, we showed that gemigliptin, a novel(More)
This paper presents a nine-phase permanent-magnet synchronous motor (PMSM) drive system based on multiple three-phase voltage source inverters. The nine-phase PMSM was developed as a traction motor for an ultrahigh-speed elevator. The mathematical model of the motor was simplified through symmetry of the system. Using the simplified model, the drive system(More)
This study evaluated the inhibitory effects of gemigliptin, a highly selective dipeptidyl peptidase-4 inhibitor, on the formation of advanced glycation end products (AGEs) and AGE cross-links with proteins in in vitro as well as in type 2 diabetic db/db mice. In in vitro assay, gemigliptin dose-dependently inhibited methylglyoxal-modified AGE-bovine serum(More)
This paper presents an application of a disturbance observer for a relative position control system. In this system, since the prefixed motion profile is not defined <i>ex ante</i>, the acceleration state which is generated based on the profile is also not available. Therefore, feedforward acceleration controls cannot be used, and the position control(More)
The conventional motion control system simply consists of a PID position controller and a disturbance observer. The estimated speed from the observer has been used to control the speed as a feedback and the estimated disturbance force, which is a byproduct of the observer, has been used to reject the disturbance. However, in this case the disturbance(More)
In this paper, a synchronous motor with an inverter integrated rotor (SMIIR) is introduced, and its control scheme is proposed. This presents a new breed of synchronous motor in that it integrates an inverter inside the rotor. The basic operational principle and control strategies are discussed. Given these new strategies, the SMIIR can be considered as a(More)
Gemigliptin, a novel dipeptidyl peptidase (DPP)-4 inhibitor, is approved for use as a monotherapy or in combination therapy to treat hyperglycemia in patients with type 2 diabetes mellitus. In this study, we investigated the pharmacological profiles of gemigliptin in vitro and in vivo and compared them to those of the other DPP-4 inhibitors. Gemigliptin was(More)
Retinal pericyte loss and neovascularization are characteristic features of diabetic retinopathy. Gemigliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, has shown robust blood-glucose lowering effects in type 2 diabetic patients, but its effects on diabetic retinopathy have not yet been reported. We evaluated the efficacy of gemigliptin on retinal(More)